THE BLOG
10/23/2013 02:55 pm ET Updated Dec 23, 2013

Drug-Resistant TB Officially a 'Crisis' - Now What?

Today, the World Health Organization (WHO) declared multi drug-resistant TB (MDR-TB) a "public health crisis" -- and released an evidence-packed report to prove it.

It was just a year ago that I wrote about what we can do to curb the spread of 'virtually untreatable tuberculosis' announced by the U.S. Centers for Disease Control and Prevention. Despite grabbing a few headlines, this news was largely greeted with what I think of as a large yawn and a polite smile; most people were more freaked out by fictitious superbugs in Hollywood films like Contagion and Outbreak.

This gaping yawn grew into a giant sleepy stretch, but the release of the WHO's annual global TB report today should be the data-filled nudge that wakes us all the way up.

The persistent creep of drug-resistant tuberculosis continues unabated. Here's a quick breakdown:

  • About 1 in 5 of the 94,000 people diagnosed with MDR-TB (resistant to two of most commonly used drugs in the current four-drug regimen) are not being treated.
  • Only about half of those being treated for drug-resistant TB are successfully completing treatment. Trends suggest this gap is only increasing.
  • 10 percent of these cases are morphing into extensively drug-resistant TB (resistant to two first line drugs and at least two second line drugs).

We've reached a point where an ancient disease is outrunning our attempts to control it. Despite some visionary political commitments -- such as recent U.S. and UK commitments to the Global Fund to Fight AIDS, Tuberculosis and Malaria -- ultimately, our global fight against TB is starved of political leadership and funding. The new WHO report reveals this massive disconnect between what is clearly a crisis situation and a lackluster global response to TB -- a disconnect demonstrated by the $2 billion we are lacking annually to mount a smart and effective response to TB in the low- and middle-income countries where it is needed most.

This makes no sense -- not from a public health perspective, or an economic perspective.

We have evidence of the oppressive and unnecessary costs associated with TB and its drug-resistant strains. A recent study showed that tuberculosis (the care of patients and the enormous costs in lost productivity) costs the European Union €5.9 billion per year. According to researchers, this estimate is conservative, as several sets of data were not available and the real costs may actually be twice as high.

There is not a national budget anywhere prepared to bear these burdens.

The good news: the solutions to this crisis are multifaceted, long-term, and outlined in the "priority actions" of the WHO report.

What can be done first?

At its Fourth Replenishment in December in Washington, D.C., the Global Fund must receive the $15 billion it is requesting from donors to scale up its programs, save more lives, and ultimately bring these three epidemics under control.

Nearly 90 percent of international donor financing for TB is provided by the Global Fund, and its programs have put 11 million people on TB treatment. In 2011, Global Fund programs supported about one-quarter of cases enrolled in MDR-TB treatment. Failing to scale up TB programs could have a catastrophic impact on the spread of drug-resistance.

TB anywhere is TB everywhere. As an airborne disease that can be spread through the simple of act of coughing, our decision makers have an obligation to heed the evidence and ramp up our slowing fight against an ancient disease, before its control spins out of our grasp.

Thanks to the WHO, we have the evidence. We know what we need to do. What we need now is visionary leadership, particularly the delivery of commitments and new resources for the Global Fund.

Subscribe to Must Reads.
The internet's best stories, and interviews with their authors.